Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12301091 | 0.86 | LMNA (0.43) | LMNASMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL2319059 | 0.85 | LMNA (0.43) | LMNASMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL2319410 | 0.84 | LMNA (0.47) | LMNASMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL2321363 | 0.84 | LMNA (0.42) | LMNASMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL2316929 | 0.84 | ALDH1A1 (0.46) | LMNASMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL2445846 | 0.84 | LMNA (0.44) | LMNASMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL2321530 | 0.84 | LMNA (0.44) | LMNASMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL2323259 | 0.83 | LMNA (0.47) | LMNASMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL12301095 | 0.83 | LMNA (0.47) | LMNASMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL2318703 | 0.83 | LMNA (0.46) | LMNASMN1; SMN2HTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230471-A1 | BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-22 | — | — | US | claimed |
| US-20110230471-A1 | BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230471-A1 | BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230471-A1 | BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN | ENPP2, TPX2, TPD52L2 | LMNA 579/4885SMN1; SMN2 4063/4885HTT 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.